152 related articles for article (PubMed ID: 32189167)
1. ASO Author Reflections: Uninsurance is Associated with Worse Outcomes Following Resection for Gastro-Entero-Pancreatic Neuroendocrine Tumors.
Marincola Smith P; Baechle JJ; Idrees K
Ann Surg Oncol; 2020 Sep; 27(9):3154-3155. PubMed ID: 32189167
[No Abstract] [Full Text] [Related]
2. ASO Author Reflection: Risk of Recurrence After Radical Resection in Entero-Pancreatic Neuroendocrine Tumors.
Merola E
Ann Surg Oncol; 2022 Sep; 29(9):5578-5579. PubMed ID: 35581515
[No Abstract] [Full Text] [Related]
3. ASO Author Reflections: Trends in the Number of Lymph Nodes Evaluated Following Resection of Pancreatic Neuroendocrine Tumors-An Increasing Adoption of the AJCC Guidelines?
Sahara K; Tsilimigras DI; Pawlik TM
Ann Surg Oncol; 2020 Apr; 27(4):1213-1214. PubMed ID: 31832917
[No Abstract] [Full Text] [Related]
4. Insurance-based Disparities in Gastro-Entero-Pancreatic Neuroendocrine Tumor Patients.
Baechle JJ; Smith PM; Idrees K
J Health Care Poor Underserved; 2021; 32(3):1199-1207. PubMed ID: 34421025
[TBL] [Abstract][Full Text] [Related]
5. ASO Author Reflections: Reconsidering Resection for Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma.
Kaslow SR; Correa-Gallego C
Ann Surg Oncol; 2022 Jun; 29(6):3532-3533. PubMed ID: 35220501
[No Abstract] [Full Text] [Related]
6. ASO Author Reflections: Patient-Reported Quality of Life in Patients with Neuroendocrine Tumors Following Surgical Resection.
Rosowicz A; Bangla VG; Divino CM
Ann Surg Oncol; 2023 Oct; 30(11):6786. PubMed ID: 37394669
[No Abstract] [Full Text] [Related]
7. ASO Author Reflections: Elevated Preoperative Specific Growth Rate is Associated with Shortened Survival After Resection for Pancreatic Neuroendocrine Tumors.
Baechle JJ; Marincola Smith P; Idrees K
Ann Surg Oncol; 2020 Oct; 27(10):3924-3925. PubMed ID: 32468347
[No Abstract] [Full Text] [Related]
8. Management of gastro-entero-pancreatic neuroendocrine tumours (GEP NET): an introduction.
Van Hootegem P; Borbath I; Verslype C
Acta Gastroenterol Belg; 2009; 72(1):27-8. PubMed ID: 19402367
[No Abstract] [Full Text] [Related]
9. ASO Author Reflections: Refining the Surgical Management of Pancreatic Neuroendocrine Tumors.
Cloyd JM; Poultsides GA
Ann Surg Oncol; 2021 Feb; 28(2):1050-1051. PubMed ID: 32974698
[No Abstract] [Full Text] [Related]
10. ASO Author Reflections: Combined Pancreatic and Hepatic Resections for Metastatic Pancreatic Neuroendocrine Tumors-A Single Operation is Feasible in Most Patients.
Gudmundsdottir H; Halfdanarson TR; Cleary SP
Ann Surg Oncol; 2022 Oct; 29(11):6958-6959. PubMed ID: 35780453
[No Abstract] [Full Text] [Related]
11. ASO Author Reflections: Can We Evaluate Surgical Quality for Pancreatic Neuroendocrine Tumors?
Fermi F; Partelli S; Falconi M
Ann Surg Oncol; 2024 Jun; 31(6):4117-4118. PubMed ID: 38564069
[No Abstract] [Full Text] [Related]
12. ASO Author Reflections: Preoperative Malignant Risk Assessment for Small (≤ 20 mm) Nonfunctioning Pancreatic Neuroendocrine Tumors.
Nanno Y; Toyama H
Ann Surg Oncol; 2023 Jun; 30(6):3501-3502. PubMed ID: 36765011
[No Abstract] [Full Text] [Related]
13. ASO Author Reflections: Lymph Node Metastasis in Pancreatic Neuroendocrine Tumor.
Tanaka M; Hackert T
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):863-864. PubMed ID: 32720037
[No Abstract] [Full Text] [Related]
14. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma.
Li MX; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Zhang XF; Pawlik TM
J Surg Oncol; 2022 Sep; 126(4):689-697. PubMed ID: 35616186
[TBL] [Abstract][Full Text] [Related]
15. ASO Author Reflections: Accuracy and Prognostic Impact of Nodal Status on Preoperative Imaging for Management of Pancreatic Neuroendocrine Tumors.
Zhang N; Zhang XF; Pawlik TM
Ann Surg Oncol; 2024 May; 31(5):2973-2974. PubMed ID: 38142259
[No Abstract] [Full Text] [Related]
16. ASO Author Reflections: Endoscopic Management is Reasonable for <2 cm Duodenal Neuroendocrine Tumors.
Tran CG; Sherman SK; Howe JR
Ann Surg Oncol; 2022 Jan; 29(1):85-86. PubMed ID: 34608558
[TBL] [Abstract][Full Text] [Related]
17. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.
Tierney JF; Chivukula SV; Wang X; Pappas SG; Schadde E; Hertl M; Poirier J; Keutgen XM
Surgery; 2019 Mar; 165(3):644-651. PubMed ID: 30366604
[TBL] [Abstract][Full Text] [Related]
18. Aggressive gastro-entero-pancreatic neoplasms.
Coriat R
Ann Endocrinol (Paris); 2019 Jun; 80(3):185-186. PubMed ID: 31064660
[No Abstract] [Full Text] [Related]
19. Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias.
Albers MB; Almquist M; Bergenfelz A; Nordenström E
Langenbecks Arch Surg; 2020 Mar; 405(2):137-143. PubMed ID: 32291468
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are.
Rossi RE; Elvevi A; Gallo C; Palermo A; Invernizzi P; Massironi S
World J Gastroenterol; 2022 Jul; 28(26):3258-3273. PubMed ID: 36051341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
